1. Home
  2. APLS vs WVE Comparison

APLS vs WVE Comparison

Compare APLS & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Apellis Pharmaceuticals Inc.

APLS

Apellis Pharmaceuticals Inc.

HOLD

Current Price

$23.49

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$13.45

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APLS
WVE
Founded
2009
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.4B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
APLS
WVE
Price
$23.49
$13.45
Analyst Decision
Buy
Strong Buy
Analyst Count
20
16
Target Price
$32.16
$30.56
AVG Volume (30 Days)
3.9M
3.8M
Earning Date
02-27-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
$1,016,397,000.00
$109,230,000.00
Revenue This Year
$31.31
N/A
Revenue Next Year
N/A
$16.10
P/E Ratio
$65.59
N/A
Revenue Growth
42.11
103.75
52 Week Low
$16.10
$5.28
52 Week High
$30.53
$21.73

Technical Indicators

Market Signals
Indicator
APLS
WVE
Relative Strength Index (RSI) 50.62 46.02
Support Level $22.29 $12.70
Resistance Level $24.10 $14.56
Average True Range (ATR) 1.18 0.78
MACD 0.15 -0.07
Stochastic Oscillator 76.65 37.06

Price Performance

Historical Comparison
APLS
WVE

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: